Last reviewed · How we verify
FF ELLIPTA DPI
At a glance
| Generic name | FF ELLIPTA DPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Dyspnoea
- Back pain
- Rhinitis allergic
- Respiratory tract infection viral
- Rhinitis
- Bronchitis
- Influenza
- Pharyngitis
- Toothache
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma (PHASE2)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF ELLIPTA DPI CI brief — competitive landscape report
- FF ELLIPTA DPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI